Aura Biosciences (AURA) Research & Development (2020 - 2026)
Aura Biosciences' (AURA) quarterly Research & Development came in at $28.0 million in Q1 2026, up 19.78% YoY from $23.3 million in Q1 2025, and up 27.69% on a QoQ basis from $21.9 million in Q4 2025.
Aura Biosciences (AURA) Research & Development (2020 - 2026) Analysis & Trends
Aura Biosciences (AURA) has 7 years of Research & Development data on file, last reported at $28.0 million in Q1 2026.
- Quarterly Research & Development rose 19.78% year-over-year to $28.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.9 million (up 19.25% YoY) and the FY2025 annual result came in at $90.3 million, up 23.19% from the prior year.
- Research & Development improved to $28.0 million in Q1 2026, from $21.9 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $28.0 million in Q1 2026 to a low of $8.3 million in Q1 2022.
- A 5-year average of $17.6 million and a median of $17.0 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 97.75% — and 2025, when it slipped 1.96%.
- Tracing AURA's Research & Development over 5 years: stood at $13.2 million in 2022, then jumped by 54.12% to $20.3 million in 2023, then grew by 10.13% to $22.3 million in 2024, then fell by 1.96% to $21.9 million in 2025, then advanced by 27.69% to $28.0 million in 2026.
- The last three Research & Development figures came in at $28.0 million (Q1 2026), $21.9 million (Q4 2025), and $22.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Aura Biosciences | 797.49 Mn | 729.65 Mn | - | 30.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.75 Mn |
| Mar 31, 2026 | 27.96 Mn |
| Dec 31, 2025 | 21.90 Mn |
| Sep 30, 2025 | 22.18 Mn |
| Jun 30, 2025 | 22.88 Mn |
| Mar 31, 2025 | 23.34 Mn |
| Dec 31, 2024 | 22.33 Mn |
| Sep 30, 2024 | 17.04 Mn |
| Jun 30, 2024 | 16.88 Mn |
| Mar 31, 2024 | 17.05 Mn |
| Dec 31, 2023 | 20.28 Mn |
| Sep 30, 2023 | 15.43 Mn |
| Jun 30, 2023 | 15.12 Mn |
| Mar 31, 2023 | 14.41 Mn |
| Dec 31, 2022 | 13.16 Mn |
| Sep 30, 2022 | 11.29 Mn |
| Jun 30, 2022 | 9.51 Mn |
| Mar 31, 2022 | 8.28 Mn |
| Dec 31, 2021 | 7.98 Mn |
| Sep 30, 2021 | 6.37 Mn |